多发性骨髓瘤骨病治疗进展  

Advanced progress on the treatment of multiple myeloma

作　　者：刘玉杰[1] 何韶辉 王达[1] 姜东杰[1] 杨兴海[1] 许炜[1] 魏海峰[1] 肖建如[1] 

机构地区：[1]第二军医大学附属长征医院骨肿瘤科,上海200003

出　　处：《中国骨与关节杂志》2018年第1期46-49,共4页Chinese Journal of Bone and Joint

摘　　要：多发性骨髓瘤（multiple myeloma,MM）是一种以多克隆浆细胞在骨髓中无限增殖扩散为特点的恶性血液系统疾病^（[1-2]）。近年来MM发病率逐年增高,已成为全球继非霍奇金淋巴瘤后的第二高发血液肿瘤^（[3]）。多发性骨髓瘤骨病（multiple myeloma bone disease,MBD）是MM最常见的并发症,超过80%的患者会出现骨损害。Multiple myeloma（ MM） is a hematologic malignancy. It is characterized by a neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Multiple myeloma-related bone disease is the most common and devastating complication of multiple myeloma bone disease（ MBD）. More than 80% of MM patients suffer from destructive bony lesions, following pain, fractures, mobility issues, and neurological deficits. In addition to stem cell transplantation, chemotherapy, radiotherapy and surgical interventions in the treatment of MM, the application and development in some new types of immune therapy and targeted therapy all play a increasingly significant role in the treatment of MBD. This review discusses an overview on the management of MBD, so as to provide reference for the clinical treatment of MBD.

关 键 词：多发性骨髓瘤骨病 骨相关事件 诊疗策略 

分 类 号：R738.1[医药卫生—肿瘤]